SG11202105795XA - Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1 - Google Patents

Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1

Info

Publication number
SG11202105795XA
SG11202105795XA SG11202105795XA SG11202105795XA SG11202105795XA SG 11202105795X A SG11202105795X A SG 11202105795XA SG 11202105795X A SG11202105795X A SG 11202105795XA SG 11202105795X A SG11202105795X A SG 11202105795XA SG 11202105795X A SG11202105795X A SG 11202105795XA
Authority
SG
Singapore
Prior art keywords
hsd1
estra
inhibitors
pyrazole ring
compounds condensed
Prior art date
Application number
SG11202105795XA
Other languages
English (en)
Inventor
Leena Hirvelä
Marjo Hakola
Tero Linnanen
Pasi Koskimies
Camilla Stjernschantz
Original Assignee
Forendo Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forendo Pharma Ltd filed Critical Forendo Pharma Ltd
Publication of SG11202105795XA publication Critical patent/SG11202105795XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036Nitrogen-containing hetero ring
    • C07J71/0057Nitrogen and oxygen
    • C07J71/0068Nitrogen and oxygen at position 16(17)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036Nitrogen-containing hetero ring
    • C07J71/0042Nitrogen only
    • C07J71/0052Nitrogen only at position 16(17)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
SG11202105795XA 2018-12-05 2019-12-05 Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1 SG11202105795XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20186056 2018-12-05
PCT/FI2019/050874 WO2020115371A1 (en) 2018-12-05 2019-12-05 Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1

Publications (1)

Publication Number Publication Date
SG11202105795XA true SG11202105795XA (en) 2021-06-29

Family

ID=69005734

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105795XA SG11202105795XA (en) 2018-12-05 2019-12-05 Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1

Country Status (15)

Country Link
US (1) US20220041647A1 (es)
EP (1) EP3891167A1 (es)
JP (1) JP7417608B2 (es)
KR (1) KR20210114390A (es)
CN (1) CN113412269A (es)
AU (2) AU2019393005B2 (es)
BR (1) BR112021010598A2 (es)
CA (1) CA3122049C (es)
CL (1) CL2021001468A1 (es)
EA (1) EA202191531A1 (es)
IL (1) IL283588A (es)
MX (1) MX2021006452A (es)
SG (1) SG11202105795XA (es)
UA (1) UA126881C2 (es)
WO (1) WO2020115371A1 (es)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1094798A2 (en) 1998-03-11 2001-05-02 Endorecherche Inc. INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
GB9929302D0 (en) 1999-12-11 2000-02-02 Univ Cardiff Benzyl tetralins compositions and uses thereof
NZ530810A (en) 2001-09-06 2006-05-26 Schering Corp 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
PE20030705A1 (es) 2001-10-17 2003-08-21 Schering Corp Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes
AU2003290799A1 (en) 2002-11-18 2004-06-15 Schering Corporation 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
ES2312845T3 (es) 2002-12-17 2009-03-01 Schering Corporation Inhibidores de la deshidrogenasa de 17 beta-hidroxiesteroides de tipo 3 para el tratamiento de enfermedades dependientes de androgenos.
WO2004085345A2 (en) 2003-03-21 2004-10-07 Yale University 15α-SUBSTITUTED ESTRADIOL CARBOXYLIC ACID ESTERS AS LOCALLY ACTIVE ESTROGENS
GB0306718D0 (en) 2003-03-24 2003-04-30 Sterix Ltd Compound
US20040224935A1 (en) 2003-04-07 2004-11-11 Endorecherche, Inc. Topical antiandrogenic steroids
US7465739B2 (en) 2003-06-10 2008-12-16 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
US7754709B2 (en) 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
TWI331154B (en) 2003-11-12 2010-10-01 Solvay Pharm Gmbh Novel 17-hydroxysteroid dehydrogenase type i inhibitors
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
DE102004032673A1 (de) 2004-07-02 2006-01-26 Schering Ag Neue 2-substituierte D-Homo-estra-1,3,5(10)-triene als Inhibitoren der 17ß-Hydroxysteroiddehydrogenase Typ 1
DE102004032674A1 (de) 2004-07-02 2006-01-26 Schering Ag Neue 2-substituierte Estra-1,3,5(10)-trien-17-one als Inhibitoren der 17β-Hydroxysteroiddehydrogenase Typ 1
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
US8030298B2 (en) 2005-05-26 2011-10-04 Abbott Products Gmbh 17β-HSD1 and STS inhibitors
CN102796160A (zh) 2005-05-26 2012-11-28 索尔瓦药物有限公司 17β-HSD1和STS抑制剂
RU2469042C2 (ru) 2006-09-19 2012-12-10 Зольвай Фармасьютиклз Гмбх Терапевтически активные триазолы и их использование
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
CN101568547B (zh) 2006-11-30 2014-06-25 索尔瓦药物有限公司 作为17βHSD抑制剂的被取代的雌三烯衍生物
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
CA2742869A1 (en) 2008-11-20 2010-05-27 President And Fellows Of Harvard College Fluorination of organic compounds
US9663549B2 (en) * 2013-06-25 2017-05-30 Forendo Pharma Ltd. Therapeutically active 17-nitrogen substituted estratreinthiazole derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase
JP6461127B2 (ja) 2013-06-25 2019-01-30 フォレンド ファーマ リミテッド 17βヒドロキシステロイド脱水素酵素、タイプIの阻害剤としての治療活性エストラトリエンチアゾール誘導体
CN105518017B (zh) 2013-06-25 2020-07-14 佛恩多制药有限公司 治疗活性的作为1型17β-羟基类固醇脱氢酶抑制剂的雌三烯噻唑衍生物
DK3634975T3 (da) * 2017-06-08 2024-05-27 Organon R&D Finland Ltd 17-oximer af 15.beta.-[3-propanamido]-substituerede estra-1,3,5(10)-trien-17-oner til anvendelse i inhibition af 17.beta.-hydroxysteroid-dehydrogenaser

Also Published As

Publication number Publication date
CL2021001468A1 (es) 2022-01-28
AU2019393005B2 (en) 2022-12-15
JP7417608B2 (ja) 2024-01-18
CN113412269A (zh) 2021-09-17
MX2021006452A (es) 2021-09-28
AU2019393005A1 (en) 2021-07-29
WO2020115371A1 (en) 2020-06-11
US20220041647A1 (en) 2022-02-10
CA3122049A1 (en) 2020-06-11
KR20210114390A (ko) 2021-09-23
CA3122049C (en) 2023-10-17
BR112021010598A2 (pt) 2021-08-24
UA126881C2 (uk) 2023-02-15
EP3891167A1 (en) 2021-10-13
JP2022510386A (ja) 2022-01-26
IL283588A (en) 2021-07-29
EA202191531A1 (ru) 2021-09-03
AU2022279473A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
IL282468A (en) 2-Amino-n-heteroaryl-nicotinamides as inhibitors of nav1.8
CA187130S (en) Vaporizer
CA185291S (en) Vaporizer
CA186350S (en) Vaporizer
HUE054690T2 (hu) 8-Oxetán-3-il-3,8-diazabiciklo[3.2.1]oktán-3-il-csoporttal szubsztituált vegyületek HIV inhibitorokként
GB2573892B (en) Low portland silica-lime cements
MX2016008851A (es) Compuesto esteroideo para su uso en el tratamiento de encefalopatia hepatica.
ZA201706520B (en) An adjuvant for a cement or a refractory concrete composition, the uses thereof, and cement and refractory concrete compositions
SG11202103356UA (en) Process for preparing short-chain olefins in the gas phase
CA185281S (en) Vaporizer
SG11202005889WA (en) Process for the preparation of methyl mercaptan
GB2564129B (en) Self-compacting concrete composition
PL3738452T3 (pl) Waporyzator
IL271218A (en) 15 beta-[3-propanoamido] ester-1, 3, 5(10)-trien-17-one substances and their 17-oximes used in the inhibition of 17 beta-hydroxysteroid dehydrogenases
IL283588A (en) Compounds 1, 3, 5(10)-triane condensed at position 16(17) with a pyrazole ring as 17-hsd1 inhibitors
EP3701064C0 (en) FORMULATION FOR CORROSION INHIBITION
ZA202204678B (en) D-amphetamine compounds, compositions, and processes for making and using the same
IL277876A (en) A preparation for the treatment of one or more estrogen-related diseases
CA187806S (en) Vaporizer
EP3845528C0 (en) PYRAZOLE COMPOUNDS, CORRESPONDING PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS IRAK4 INHIBITORS
SG10201807686QA (en) An Article For Enriching Soil Fertility
PL3589622T3 (pl) Sposób przygotowywania jodku 3,7-bis(dimetyloamino)fenotiazyn-5-yliowego
CA185971S (en) Vaporizer
CA191408S (en) Shirt
ZA202204152B (en) A solubilizing composition